Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




High Blood Sugar Associated with Lower Risk of Benign Tumors

By LabMedica International staff writers
Posted on 07 Jul 2016
Meningioma, is a primary tumor arising from the membrane surrounding the brain and spinal cord, accounts for more than one-third of all primary brain and central nervous system tumors.

The discovery that benign brain tumors that have previously been tied to obesity and diabetes are less likely to emerge in those with high blood sugar and this could shed light on the development of meningiomas, that are usually not cancerous but that can require risky surgery and affect a patient's quality of life.

Scientists at Ohio State University (Columbus, OH, USA) and their Swedish colleagues conducted a cohort study to evaluate the potential effects of obesity-related prediagnostic glucose, triglycerides and cholesterol on meningioma and of prediagnostic meningioma on these biomarkers. They identified 41,355 individuals in the Apolipoprotein MOrtality RISk cohort with values for these biomarkers within 15 years before meningioma diagnosis, death, migration or the end of follow-up.

Meningioma was diagnosed in 181 women and 115 men whose median follow-up time was seven years. Fasting serum glucose level was inversely related to meningioma among women, but not men. Women with the highest fasting blood sugar were less than half as likely as those with the lowest readings to develop a tumor. When they compared the less-reliable non-fasting sugar readings, those taken without a period of no food or drink that could influence the results, they found that both men and women with high blood sugar had a lower likelihood of meningioma diagnosis.

The authors concluded paradoxically, hyperglycemia is inversely associated with meningioma in women. This finding does not necessarily negate the positive role of obesity or diabetes in meningioma development; rather, it may indicate that their effects depend on the stage of development. Furthermore, the prediagnostic tumor may reduce serum cholesterol levels.

Judith Schwartzbaum, PhD, a professor and the lead author of the study, said, “It's so unexpected. Usually diabetes and high blood sugar raises the risk of cancer, and it's the opposite here. These tumors take years to develop, and an earlier diagnosis would certainly lead to better surgical outcomes. It's also possible that sugar levels dip during early tumor development because the tumor is using glucose to grow.” The study was published on June 2, 2016, in the British Journal of Cancer.

Related Links:
Ohio State University


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Myeloperoxidase Assay
IDK MPO ELISA
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.